SHL Telemedicine Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: IL0010855885
CHF
1.14
0.09 (8.57%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About SHL Telemedicine Ltd. stock-summary
stock-summary
SHL Telemedicine Ltd.
Pharmaceuticals & Biotechnology
SHL Telemedicine Ltd (SHL) is an Israel-based company engaged in developing and marketing personal telemedicine solutions, with a focus on cardiovascular and related diseases. Personal telemedicine is the transmission of medical data by an individual, from a remote location, to a medical call center through telecommunication networks. SHL’s platform offers solutions to subscribing patients, health insurance companies, hospitals, clinics, physicians and other health care providers. Its solutions for healthcare professionals include: CHF monitoring service that supports patients suffering from Congestive Heart Failure; COPD monitoring service that supports patients suffering from Chronic Obstructive Pulmonary Disease, and Readmission Solutions for reducing heart-related readmissions. Its consumers' solutions include Cardiac Monitoring Service.
Company Coordinates stock-summary
Company Details
90 Yigal Alon St. , TEL AVIV-YAFO None : 67891
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.01%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Yariv Alroy
Chairman of the Board
Mr. Yehoshua Abramovich
Board of Director
Mr. Erez Alroy
Non-Executive Director
Mr. Yi He
Non-Executive Director
Dr. Amir Lerman
Non-Executive Director
Ms. Hava Shechter
Non-Executive Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
11 Million
(Quarterly Results - Jun 2015)
Net Profit:
-1 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CHF 27 Million ()

stock-summary
P/E

15.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.02

stock-summary
Return on Equity

4.31%

stock-summary
Price to Book

0.89